ASX - By Stock
|
NEU |
Re:
Acadia
|
|
Epichemist
|
1.6K |
833K |
6 |
08/08/25 |
08/08/25 |
ASX - By Stock
|
1.6K
|
833K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
Epichemist
|
1.6K |
833K |
11 |
04/08/25 |
04/08/25 |
ASX - By Stock
|
1.6K
|
833K
|
11
|
|
ASX - By Stock
|
AVH |
Re:
Still largest shareholders
|
|
Epichemist
|
64 |
19K |
3 |
31/07/25 |
31/07/25 |
ASX - By Stock
|
64
|
19K
|
3
|
|
ASX - By Stock
|
EYE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Epichemist
|
44 |
11K |
4 |
30/07/25 |
30/07/25 |
ASX - By Stock
|
44
|
11K
|
4
|
|
ASX - By Stock
|
AVH |
Re:
Ann: AVITA Medical to Announce 2nd Quarter 2025 Financial Results
|
|
Epichemist
|
9 |
3.4K |
5 |
29/07/25 |
29/07/25 |
ASX - By Stock
|
9
|
3.4K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
Epichemist
|
1.6K |
833K |
28 |
26/07/25 |
26/07/25 |
ASX - By Stock
|
1.6K
|
833K
|
28
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
12 |
24/07/25 |
24/07/25 |
ASX - By Stock
|
16K
|
8.1M
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
4 |
22/07/25 |
22/07/25 |
ASX - By Stock
|
16K
|
8.1M
|
4
|
|
ASX - By Stock
|
AVH |
Re:
Still largest shareholders
|
|
Epichemist
|
64 |
19K |
3 |
21/07/25 |
21/07/25 |
ASX - By Stock
|
64
|
19K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
43 |
13/07/25 |
13/07/25 |
ASX - By Stock
|
16K
|
8.1M
|
43
|
|
ASX - By Stock
|
NEU |
Re:
M&A
|
|
Epichemist
|
249 |
138K |
2 |
02/07/25 |
02/07/25 |
ASX - By Stock
|
249
|
138K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
7 |
01/07/25 |
01/07/25 |
ASX - By Stock
|
16K
|
8.1M
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
17 |
28/06/25 |
28/06/25 |
ASX - By Stock
|
16K
|
8.1M
|
17
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
21 |
28/06/25 |
28/06/25 |
ASX - By Stock
|
16K
|
8.1M
|
21
|
|
ASX - By Stock
|
CUV |
Re:
Ann: German Non-deal Roadshow Presentation
|
|
Epichemist
|
20 |
9.0K |
7 |
24/06/25 |
24/06/25 |
ASX - By Stock
|
20
|
9.0K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
9 |
20/06/25 |
20/06/25 |
ASX - By Stock
|
16K
|
8.1M
|
9
|
|
ASX - By Stock
|
CUV |
Re:
Communique number 2
|
|
Epichemist
|
11 |
4.9K |
10 |
17/06/25 |
17/06/25 |
ASX - By Stock
|
11
|
4.9K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
4 |
13/06/25 |
13/06/25 |
ASX - By Stock
|
16K
|
8.1M
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
Epichemist
|
1.8K |
1.0M |
21 |
02/06/25 |
02/06/25 |
ASX - By Stock
|
1.8K
|
1.0M
|
21
|
|
ASX - By Stock
|
NEU |
Re:
Ann: NEU receives FDA minutes and re-confirms Phase 3 endpoints
|
|
Epichemist
|
8 |
6.6K |
9 |
13/05/25 |
13/05/25 |
ASX - By Stock
|
8
|
6.6K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
31 |
12/05/25 |
12/05/25 |
ASX - By Stock
|
16K
|
8.1M
|
31
|
|
ASX - By Stock
|
AVH |
Re:
Ann: AVITA Medical to Announce First Quarter 2025 Results
|
|
Epichemist
|
42 |
16K |
0 |
09/05/25 |
09/05/25 |
ASX - By Stock
|
42
|
16K
|
0
|
|
ASX - By Stock
|
CUV |
Re:
Ann: CUV recruits 200 patients in Phase III vitiligo trial CUV105
|
|
Epichemist
|
21 |
8.1K |
10 |
07/05/25 |
07/05/25 |
ASX - By Stock
|
21
|
8.1K
|
10
|
|
ASX - By Stock
|
CUV |
Re:
Ann: CUV recruits 200 patients in Phase III vitiligo trial CUV105
|
|
Epichemist
|
21 |
8.1K |
9 |
07/05/25 |
07/05/25 |
ASX - By Stock
|
21
|
8.1K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
39 |
29/04/25 |
29/04/25 |
ASX - By Stock
|
16K
|
8.1M
|
39
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
Epichemist
|
1.6K |
833K |
18 |
24/04/25 |
24/04/25 |
ASX - By Stock
|
1.6K
|
833K
|
18
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Notification regarding unquoted securities - CUV
|
|
Epichemist
|
5 |
3.1K |
1 |
23/04/25 |
23/04/25 |
ASX - By Stock
|
5
|
3.1K
|
1
|
|
ASX - By Stock
|
EYE |
Re:
Ann: Change in substantial shareholding from AEF
|
|
Epichemist
|
32 |
10K |
5 |
20/04/25 |
20/04/25 |
ASX - By Stock
|
32
|
10K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
28 |
16/04/25 |
16/04/25 |
ASX - By Stock
|
16K
|
8.1M
|
28
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
15 |
15/04/25 |
15/04/25 |
ASX - By Stock
|
16K
|
8.1M
|
15
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
21 |
10/04/25 |
10/04/25 |
ASX - By Stock
|
16K
|
8.1M
|
21
|
|
ASX - By Stock
|
AVH |
Re:
Ann: AVH Launches Cohealyx, Expanding U.S. Market Opportunity
|
|
Epichemist
|
25 |
8.8K |
9 |
07/04/25 |
07/04/25 |
ASX - By Stock
|
25
|
8.8K
|
9
|
|
ASX - By Stock
|
AVH |
Re:
Ann: AVH Launches Cohealyx, Expanding U.S. Market Opportunity
|
|
Epichemist
|
25 |
8.8K |
3 |
07/04/25 |
07/04/25 |
ASX - By Stock
|
25
|
8.8K
|
3
|
|
ASX - By Stock
|
CUV |
Re:
Clinuvel and Pro Medicus side by side
|
|
Epichemist
|
52 |
20K |
0 |
06/04/25 |
06/04/25 |
ASX - By Stock
|
52
|
20K
|
0
|
|
ASX - By Stock
|
CUV |
Re:
Clinuvel and Pro Medicus side by side
|
|
Epichemist
|
52 |
20K |
1 |
06/04/25 |
06/04/25 |
ASX - By Stock
|
52
|
20K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
13 |
05/04/25 |
05/04/25 |
ASX - By Stock
|
16K
|
8.1M
|
13
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
20 |
05/04/25 |
05/04/25 |
ASX - By Stock
|
16K
|
8.1M
|
20
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
6 |
05/04/25 |
05/04/25 |
ASX - By Stock
|
16K
|
8.1M
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Epichemist
|
16K |
8.1M |
10 |
05/04/25 |
05/04/25 |
ASX - By Stock
|
16K
|
8.1M
|
10
|
|
ASX - By Stock
|
BGL |
Re:
Ann: Voluntary suspension update
|
|
Epichemist
|
57 |
36K |
11 |
04/04/25 |
04/04/25 |
ASX - By Stock
|
57
|
36K
|
11
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Update - Notification of buy-back - NEU
|
|
Epichemist
|
28 |
10K |
28 |
02/04/25 |
02/04/25 |
ASX - By Stock
|
28
|
10K
|
28
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Type C Meeting granted by FDA for Phelan-McDermid syndrome
|
|
Epichemist
|
84 |
43K |
17 |
02/04/25 |
02/04/25 |
ASX - By Stock
|
84
|
43K
|
17
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Type C Meeting granted by FDA for Phelan-McDermid syndrome
|
|
Epichemist
|
84 |
43K |
3 |
02/04/25 |
02/04/25 |
ASX - By Stock
|
84
|
43K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Type C Meeting granted by FDA for Phelan-McDermid syndrome
|
|
Epichemist
|
84 |
43K |
1 |
02/04/25 |
02/04/25 |
ASX - By Stock
|
84
|
43K
|
1
|
|
ASX - By Stock
|
PTX |
Re:
Time to stay focused
|
|
Epichemist
|
9 |
4.3K |
3 |
28/03/25 |
28/03/25 |
ASX - By Stock
|
9
|
4.3K
|
3
|
|
ASX - By Stock
|
CUV |
Re:
BB delay explanation?
|
|
Epichemist
|
15 |
6.6K |
7 |
27/03/25 |
27/03/25 |
ASX - By Stock
|
15
|
6.6K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Update - Notification of buy-back - NEU
|
|
Epichemist
|
20 |
8.3K |
8 |
26/03/25 |
26/03/25 |
ASX - By Stock
|
20
|
8.3K
|
8
|
|
ASX - By Stock
|
EYE |
Re:
Invest Webinar - Half Year Results
|
|
Epichemist
|
31 |
8.8K |
16 |
25/03/25 |
25/03/25 |
ASX - By Stock
|
31
|
8.8K
|
16
|
|
ASX - By Stock
|
EYE |
Re:
Invest Webinar - Half Year Results
|
|
Epichemist
|
31 |
8.8K |
2 |
25/03/25 |
25/03/25 |
ASX - By Stock
|
31
|
8.8K
|
2
|
|
ASX - By Stock
|
EYE |
Re:
Invest Webinar - Half Year Results
|
|
Epichemist
|
31 |
8.8K |
1 |
25/03/25 |
25/03/25 |
ASX - By Stock
|
31
|
8.8K
|
1
|
|